Research study Program year 2023 Source: CMS Open Payments

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinet

Research payments

$1,013,793

63 payments

Through program year 2023, $1,013,793 in research payments was reported against A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinet, across 63 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$151,869	8
2022	Research	$821,862	48
2021	Research	$40,062	7

Breakdown

Who paid Research payments · program years 2021–2023

GlaxoSmithKline, LLC. $1,013,793 63 payments

Who received the money Research payments · program years 2021–2023

American Research Corp Organisation paid for research $715,025 25 payments
Orlando Clinical Research Organisation paid for research $298,768 38 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

2 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.